Volixibat (BioDeep_00000802792)
代谢物信息卡片
化学式: C38H51N3O12S2 (805.2914)
中文名称: 伏昔巴特
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)C(C1O)C3=CC(=CC=C3)NC(=O)NC4C(C(C(C(O4)COS(=O)(=O)O)O)OCC5=CC=CC=C5)O)CC
InChI: InChI=1S/C38H51N3O12S2/c1-5-7-18-38(6-2)23-54(46,47)30-17-16-27(41(3)4)20-28(30)31(35(38)44)25-14-11-15-26(19-25)39-37(45)40-36-33(43)34(51-21-24-12-9-8-10-13-24)32(42)29(53-36)22-52-55(48,49)50/h8-17,19-20,29,31-36,42-44H,5-7,18,21-23H2,1-4H3,(H2,39,40,45)(H,48,49,50)/t29-,31-,32-,33-,34+,35-,36-,38-/m1/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C177170 - Ileal Bile Acid Transport Inhibitor
C26170 - Protective Agent > C2081 - Hepatoprotective Agent
D057847 - Lipid Regulating Agents
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Philip N Newsome, Melissa Palmer, Bradley Freilich, Muhammad Y Sheikh, Aasim Sheikh, Harry Sarles, Robert Herring, Parvez Mantry, Zeid Kayali, Tarek Hassanein, Hak-Myung Lee, Guruprasad P Aithal. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Journal of hepatology.
2020 08; 73(2):231-240. doi:
10.1016/j.jhep.2020.03.024. [PMID: 32234329] - Kanita Salic, Robert Kleemann, Cynthia Wilkins-Port, John McNulty, Lars Verschuren, Melissa Palmer. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.
PloS one.
2019; 14(6):e0218459. doi:
10.1371/journal.pone.0218459. [PMID: 31233523] - Melissa Palmer, Lee Jennings, Debra G Silberg, Caleb Bliss, Patrick Martin. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
BMC pharmacology & toxicology.
2018 03; 19(1):10. doi:
10.1186/s40360-018-0200-y. [PMID: 29548345] - Nicholas Siebers, Melissa Palmer, Debra G Silberg, Lee Jennings, Caleb Bliss, Patrick T Martin. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study.
European journal of drug metabolism and pharmacokinetics.
2018 Feb; 43(1):91-101. doi:
10.1007/s13318-017-0429-7. [PMID: 28702877] - Renger G Tiessen, Ciara A Kennedy, Bradley T Keller, Nancy Levin, Lisette Acevedo, Bronislava Gedulin, Andre A van Vliet, Alejandro Dorenbaum, Melissa Palmer. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
BMC gastroenterology.
2018 Jan; 18(1):3. doi:
10.1186/s12876-017-0736-0. [PMID: 29304731]
